Abstract
Colorectal cancer (CRC) is the fourth most common cancer in the world. If detected at an early stage, treatment often might lead to cure. Of course prevention is better than cure. Epidemiological studies reveal that having a healthy diet often protects from CRC development. An important consideration in evaluating new drugs and devices is determining whether a product can effectively treat a targeted disease. There are a number of agents making their way into clinical trials by estimating their effects on biomarkers expression. Also, some are awaiting the preclinical efficacy and safety results to enter into clinical trials. Oncologic researchers are facing challenges in modifying trial design and defining the right control population, validating biomarker assays from the biological and analytical perspective. However, the results are disappointing from many of the large clinical trials. To avoid these disappointments, selection of biomarkers and its target agents needs to be evaluated in appropriate animal models for their efficacies as well as toxicities. This review focuses on the few of the potential molecular targets and their biomarkers in CRC development.
Current Enzyme Inhibition
Title: Colorectal Carcinogensis and Suppression of Tumor Development by Inhibition of Enzymes and Molecular Targets
Volume: 5 Issue: 1
Author(s): Yumiko Yasui, Mihe Kim, Takeru Oyama and Takuji Tanaka
Affiliation:
Abstract: Colorectal cancer (CRC) is the fourth most common cancer in the world. If detected at an early stage, treatment often might lead to cure. Of course prevention is better than cure. Epidemiological studies reveal that having a healthy diet often protects from CRC development. An important consideration in evaluating new drugs and devices is determining whether a product can effectively treat a targeted disease. There are a number of agents making their way into clinical trials by estimating their effects on biomarkers expression. Also, some are awaiting the preclinical efficacy and safety results to enter into clinical trials. Oncologic researchers are facing challenges in modifying trial design and defining the right control population, validating biomarker assays from the biological and analytical perspective. However, the results are disappointing from many of the large clinical trials. To avoid these disappointments, selection of biomarkers and its target agents needs to be evaluated in appropriate animal models for their efficacies as well as toxicities. This review focuses on the few of the potential molecular targets and their biomarkers in CRC development.
Export Options
About this article
Cite this article as:
Yasui Yumiko, Kim Mihe, Oyama Takeru and Tanaka Takuji, Colorectal Carcinogensis and Suppression of Tumor Development by Inhibition of Enzymes and Molecular Targets, Current Enzyme Inhibition 2009; 5 (1) . https://dx.doi.org/10.2174/157340809787314247
DOI https://dx.doi.org/10.2174/157340809787314247 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic: Diagnostic and Therapeutic Optical Imaging Techniques]
Current Medical Imaging Circulating Biomarkers for Tumor Angiogenesis: Where Are We?
Current Medicinal Chemistry The Biology of the Sodium Iodide Symporter and its Potential for Targeted Gene Delivery
Current Cancer Drug Targets Epidemiology of Upper Gastrointestinal Damage Associated with Low-Dose Aspirin
Current Pharmaceutical Design Development of Method for Three-Point Data Estimation and SVR-QSAR Model to Screen Anti Cancer Leads
Combinatorial Chemistry & High Throughput Screening Vascular Disease and Insulin-Like Growth Factor-1
Vascular Disease Prevention (Discontinued) Molecular Evidence of Compound Kushen Injection Against Lung Cancer: A Network Pharmacology-Based Investigation from Western Medicine to Traditional Medicine
Anti-Cancer Agents in Medicinal Chemistry Targeting Inhibitor of Apoptosis Proteins (IAPs) for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Functional Foods: Salient Features and Clinical Applications
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication
Current Drug Metabolism Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers
Recent Patents on CNS Drug Discovery (Discontinued) Cancer T Cell Immunotherapy with Bispecific Antibodies and Chimeric Antigen Receptors
Recent Patents on Anti-Cancer Drug Discovery Efficacy and Safety of the Combination of Docetaxel (Taxotere®) with Targeted Therapies in the Treatment of Solid Malignancies
Current Drug Targets Functional Nanoplatforms for Enhancement of Chemotherapeutic Index
Anti-Cancer Agents in Medicinal Chemistry Furanodienone: An Emerging Bioactive Furanosesquiterpenoid
Current Organic Chemistry Inhibitors for Metastasis Development
Recent Patents on Anti-Cancer Drug Discovery Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome
Current Signal Transduction Therapy Can Dietary Polyphenols Prevent the Formation of Toxic Compounds from Maillard Reaction?
Current Drug Metabolism Genomics and Proteomics of Nucleoside Transporters
Current Pharmacogenomics Identification of Multiple Subcellular Locations for Proteins in Budding Yeast
Current Bioinformatics